Last updated on November 2019

A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)


Brief description of study

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.

Clinical Study Identifier: NCT04044690

Find a site near you

Start Over

CSLB Research Site

Fukui, Japan
3.2miles
  Connect »